| |

Home Page

Novo Nordisk A/S - Reduction of the share capital
By: Nasdaq / GlobenewsWire - 24 Apr 2019Back to overview list

Bagsværd, Denmark, 24 April 2019 - At Novo Nordisk's Annual General Meeting on 21 March 2019, it was decided to reduce the company's B share capital from DKK 382,512,800 to DKK 372,512,800 by cancellation of part of the company's portfolio of own B shares equal to a nominal value of DKK 10,000,000 divided into 50,000,000 B shares of DKK 0.20 each.

Today, Novo Nordisk has registered the implementation of the reduction of the share capital with the Danish Business Authority and cancelled B shares at a nominal value of DKK 10,000,000. After the reduction of the share capital, the company's share capital is nominally DKK 480,000,000, which is divided into an A share capital of nominally DKK 107,487,200 and a B share capital of nominally DKK 372,512,800.

The reduction of the share capital will not affect Novo Nordisk's share repurchase programme which will continue as previously announced.

Further information

Anne Margrethe Hauge +45 4442 3450
Ken Inchausti (US) +1 609 786 8316
Peter Hugreffe Ankersen +45 3075 9085
Valdemar Borum Svarrer +45 3079 0301
Ann Søndermølle Rendbæk +45 3075 2253
Kristoffer Due Berg (US) +1 609 235 2989

Company announcement no. 24 / 2019



Copyright 2019 Nasdaq / GlobenewsWire Back to overview list
to the top ↑